Search
forLearn
5 / 801 resultslearn Amalaki
learn Actsyl®
learn Shikakai
learn Shankh bhasm
Research
5 / 611 resultsresearch Akala Palitya: An Ayurvedic Review
Premature graying of hair is increasing due to stress, genetics, and pollution.
research An Exploratory Review of Madhuka Taila Prati Marsha Nasya in Akala Palitya - Premature Greying of Hair
Modern lifestyle factors like stress and pollution cause premature greying of hair.
research A Critical Evaluation on Akala Palitam
Premature graying of hair is linked to an imbalance of body energies in Ayurveda and treatment varies based on the specific imbalance.
research AYURVEDIC COSMETOLOGY APPROACHES TO PREMATURE HAIR GREYING (AKĀLAPĀLITYA): A LITERATURE REVIEW
Ayurveda suggests natural remedies and lifestyle changes for managing premature hair greying.
research EFFICACY OF MADHUKA TAILA NASYA AND JAPAAKUSUMA LEPA IN AKAALAPALITYA-A SINGLE CASE STUDY
Ayurvedic treatments showed promise in treating premature graying of hair without harmful effects.
Community Join
5 / 1000+ resultscommunity 2nd Year Update FINASTERIDE ONLY from the PHILIPPINEE
A 48-year-old male from the Philippines shared his two-year progress using finasteride only for hair regrowth, experiencing significant improvement without minoxidil. He started with 0.5mg and increased to 1.25mg, later adjusting to every other day due to elevated liver enzymes, and reported 90% hair restoration.
community is there any news about pp405 please
There is no new information on pp405, with data collection expected to finish by the end of 2025. Users are discussing the timeline for data analysis and completion of Pelage Pharmaceuticals' phase 2 study.
community Pyrilutamide PHASE 2 Results just one months to go. Are you excited???🤩
Pyrilutamide, a potential topical treatment for male pattern baldness, and the user's anticipation of its Phase 2 trial results. Several users discussed their experiences with Finasteride and RU58841, while others voiced skepticism about the efficacy of Pyrilutamide.
community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community PP405 2a study was a safety study. Some rational explaining.
The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.